Generic Medicine Info
May be taken with or without food. Oral soln may be taken directly or diluted in a glass of water.
Special Precautions
Patient with QTc-interval prolongation, pre-existing cardiac disease, electrolyte disturbances. The total daily dose and administration frequency should be the same or maintained when switching between oral and IV form. Avoid abrupt withdrawal. Renal and severe hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, fatigue or coordination difficulties; if affected, do not drive or operate machinery. Monitoring Parameters Assess renal function before starting treatment especially in patients with severely impaired hepatic function. Monitor therapeutic response (e.g. seizure activity, type, duration) at the start and throughout the treatment; diastolic blood pressure (in children 1 month to <4 years); signs and symptoms of CNS depression or hypersensitivity reaction. Observe for emergence or worsening of depression, suicidal thoughts, and unusual changes in mood or behaviour.
Adverse Reactions
Significant: Suicidal ideation and behaviour; psychotic symptoms and behavioural abnormalities (e.g. irritability, aggressiveness); somnolence, fatigue, coordination difficulties; serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis); increased blood pressure (in patients 1 month to <4 years). Rarely, acute kidney injury, decreased blood cell counts (e.g. agranulocytosis, leucopenia, neutropenia, thrombocytopenia, pancytopenia); exacerbated seizure frequency or severity; prolonged QT interval. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Abdominal pain, nausea, vomiting, diarrhoea, dyspepsia. General disorders and administration site conditions: Lethargy, asthenia. Infections and infestations: Influenza. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Neck pain. Nervous system disorders: Headache, dizziness, balance disorder, tremor. Psychiatric disorders: Anxiety, depression, hostility, insomnia, nervousness. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, cough, pharyngitis, nasal congestion, pharyngolaryngeal pain. Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Anaphylaxis or angioedema.
Drug Interactions
Increased serum concentration of methotrexate. May decreased the efficacy of oral levetiracetam when taken with osmotic laxative macrogol. May increase risk of QT interval prolongation with drugs affecting QTc-interval.
CIMS Class
ATC Classification
N03AX14 - levetiracetam ; Belongs to the class of other antiepileptics.
Disclaimer: This information is independently developed by CIMS based on levetiracetam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in